Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 7691 results

  1. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

    Awaiting development [GID-TA11011] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

    Awaiting development [GID-TA10967] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development [GID-TA11404] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Third molars (impacted) - prophylactic removal [ID898]

    In development [GID-TAG525] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Nipocalimab for treating generalised myasthenia gravis TS ID 11958

    Awaiting development [GID-TA11492] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    Awaiting development [GID-TA10747] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Bipolar disorder: assessment and management (extraordinary review)

    In development [GID-NG10380] Expected publication date: TBC

    NICE guideline
    In development

  11. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Awaiting development [GID-TA11442] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    In development [GID-TA10316] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918

    Awaiting development [GID-TA11429] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    In development [GID-TA11005] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. 10395 - Aprocitentan for treating resistant hypertension TS ID 10395

    Awaiting development [GID-TA11459] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development